Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review
- PMID: 33567904
- PMCID: PMC8482705
- DOI: 10.1177/1073274820983028
Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review
Abstract
Background: There is currently no consensus on optimal management of patients with primary or recurrent non-resectable/residual retroperitoneal sarcomas (RPS). The objective of this study was to document the outcomes of patients with primary or recurrent non-resectable/residual RPS treated in our center with definitive radiotherapy (RT) and to perform a systematic review on the topic.
Methods: A retrospective analysis of consecutive RPS patients treated in our center between 2000 and 2019 was performed. All consecutive patients who underwent definitive conformal RT with image guidance for primary or recurrent non-resectable or macroscopically residual RPS were included. Additionally, a systematic review compliant with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses was performed.
Results: The study enrolled 14 patients who met the aforementioned criteria. Data on clinicopathological characteristics, RT and response to treatment were assessed. RT allowed achieving prolonged local control of the disease, i.e. no local progression of the disease for more than 12 months after RT in 10 patients. Local control lasted more than 24 months in 6 cases, with minimal or no toxicity. A systemic review of 11 studies revealed concordance of our results with previous reports of primary or recurrent non-resectable/residual RPS.
Conclusions: RT provided satisfactory local disease control with acceptable treatment tolerance in patients with primary or recurrent non-resectable/residual RPS and represents a valuable treatment modality in the selected group of patients. Additional RT modalities i.e. BT, particle therapy, MRI-guided RT, or GRID/Lattice RT may be introduced to improve local control and further minimize toxicity.
Keywords: abdominal neoplasms; image-guided radiotherapy; intensity-modulated radiotherapy; radiotherapy; retroperitoneal neoplasms; sarcoma.
Conflict of interest statement
Similar articles
-
Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas.Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):469-75. doi: 10.1016/s0360-3016(01)02595-0. Int J Radiat Oncol Biol Phys. 2002. PMID: 11872294
-
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience.Radiat Oncol. 2017 Dec 8;12(1):198. doi: 10.1186/s13014-017-0920-y. Radiat Oncol. 2017. PMID: 29216884 Free PMC article. Clinical Trial.
-
Outcomes of preoperative radiotherapy and resection of retroperitoneal sarcoma.ANZ J Surg. 2013 May;83(5):336-41. doi: 10.1111/j.1445-2197.2012.06211.x. Epub 2012 Sep 3. ANZ J Surg. 2013. PMID: 22943678
-
Progress in Retroperitoneal Sarcoma Management: Surgical and Radiotherapy Approaches.Semin Radiat Oncol. 2024 Apr;34(2):164-171. doi: 10.1016/j.semradonc.2024.02.002. Semin Radiat Oncol. 2024. PMID: 38508781 Review.
-
Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience.Am J Clin Oncol. 2005 Jun;28(3):310-6. doi: 10.1097/01.coc.0000158441.96455.31. Am J Clin Oncol. 2005. PMID: 15923806 Review.
Cited by
-
Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS).Cancers (Basel). 2023 Jun 15;15(12):3194. doi: 10.3390/cancers15123194. Cancers (Basel). 2023. PMID: 37370803 Free PMC article. Review.
-
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.Ann Surg Oncol. 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29. Ann Surg Oncol. 2022. PMID: 35767103 Review.
-
Management of Recurrent Retroperitoneal Sarcoma.Curr Oncol. 2023 Feb 25;30(3):2761-2769. doi: 10.3390/curroncol30030209. Curr Oncol. 2023. PMID: 36975422 Free PMC article. Review.
-
Complete metabolic response after Partially Ablative Radiotherapy (PAR) for bulky retroperitoneal liposarcoma: A case report.Radiol Case Rep. 2023 Nov 6;19(1):305-309. doi: 10.1016/j.radcr.2023.10.024. eCollection 2024 Jan. Radiol Case Rep. 2023. PMID: 38028304 Free PMC article.
References
-
- Gatta G, Capocaccia R, Botta L, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncol. 2017;18(8):1022–1039. doi:10.1016/S1470-2045(17)30445-X - PubMed
-
- Rutkowski P. Current therapy of retroperitoneal sarcomas. Oncol Clin Pract. 2018;14(6):348–353. doi:10.5603/OCP.2018.0048
-
- Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002–1009. doi:10.1097/SLA.0000000000001447 - PubMed
-
- Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–37. doi:10.1200/JCO.2008.18.0802 - PubMed
-
- Kirane A, Crago AM. The importance of surgical margins in retroperitoneal sarcoma. J Surg Oncol. 2016;113(3):270–276. doi:10.1002/jso.24135 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous